G. Gatta, L. Botta, M. J. Sánchez, L. A. Anderson, D. Pierannunzio et al., Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study, Eur J Cancer, vol.51, issue.15, pp.2130-2143, 2015.

E. M. Sturgis and P. M. Cinciripini, Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer, vol.110, pp.1429-1464, 2007.

S. Marur, D. Souza, G. Westra, W. H. Forastiere, and A. A. , HPV-associated head and neck cancer: a virus-related cancer epidemic, Lancet Oncol, vol.11, issue.8, pp.781-790, 2010.

H. Mehanna, T. Beech, T. Nicholson, I. El-hariry, C. Mcconkey et al., Prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region, Head Neck, vol.35, issue.5, pp.747-55, 2013.

T. Y. Seiwert and E. E. Cohen, State-of-the-art management of locally advanced head and neck cancer, Br J Cancer, vol.92, issue.8, pp.1341-1349, 2005.

J. S. Cooper, T. F. Pajak, A. Forastiere, J. Jacobs, K. K. Fu et al., Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck, vol.20, pp.588-94, 1998.

S. Marur and A. A. Forastiere, Head and neck cancer: changing epidemiology, diagnosis, and treatment, Mayo Clin Proc, vol.83, issue.4, pp.489-501, 2008.

V. Grégoire, J. L. Lefebvre, L. Licitra, E. Felip, and . Group, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, issue.5, pp.184-190, 2010.

, A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group, Br J Cancer, 1990.

C. Jacobs, G. Lyman, E. Velez-garcía, K. S. Sridhar, W. Knight et al., A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck, J Clin Oncol, vol.10, issue.2, pp.257-63, 1992.

A. A. Forastiere, B. Metch, D. E. Schuller, J. F. Ensley, L. F. Hutchins et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study, J Clin Oncol, vol.10, issue.8, pp.1245-51, 1992.

M. K. Gibson, Y. Li, B. Murphy, M. H. Hussain, and R. C. Deconti,

, Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group, J Clin Oncol, vol.23, issue.15, pp.3562-3569, 2005.

B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere, Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study, J Clin Oncol, vol.23, issue.34, pp.8646-54, 2005.

J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, vol.359, issue.11, pp.1116-1143, 2008.

R. L. Ferris, G. Blumenschein, F. J. Jr, J. Guigay, A. D. Colevas et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, vol.375, pp.1856-1867, 2016.

J. Bauml, T. Y. Seiwert, D. G. Pfister, F. Worden, S. V. Liu et al., Pembrolizumab for Platinum-and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study, J Clin Oncol, 2017.

, May, vol.10, issue.14, pp.1542-1549

L. Licitra, R. Mesia, F. Rivera, E. Remenár, R. Hitt et al., Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study, Ann Oncol, vol.22, issue.5, pp.1078-87, 2011.

J. P. Machiels, R. I. Haddad, F. J. Licitra, L. F. Tahara, M. Vermorken et al.,

, Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial, Lancet Oncol, vol.16, issue.5, pp.583-94, 2015.

J. S. Stewart, E. E. Cohen, L. Licitra, C. M. Van-herpen, C. Khorprasert et al., Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck

, J Clin Oncol, vol.27, issue.11, pp.1864-71, 2009.

M. Siano, F. Molinari, V. Martin, N. Mach, M. Früh et al., Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer, 2017.

P. Bossi, C. Bergamini, M. Siano, C. Rocca, M. Sponghini et al., Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab, Clin Cancer Res, vol.22, issue.15, pp.3961-70, 2016.

P. S. Hammerman, D. N. Hayes, and J. R. Grandis, Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov, vol.5, pp.239-283, 2015.
DOI : 10.1158/2159-8290.cd-14-1205

URL : http://cancerdiscovery.aacrjournals.org/content/5/3/239.full.pdf

S. Ausoni, P. Boscolo-rizzo, B. Singh, M. C. Da-mosto, G. Spinato et al., Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives, Cancer Metastasis Rev, vol.35, issue.3, pp.413-439, 2016.

L. A. Dunn, M. G. Fury, H. Xiao, S. S. Baxi, E. J. Sherman et al., A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Ann Oncol, vol.28, issue.10, pp.2533-2538, 2017.

A. Jimeno, K. Shirai, M. Choi, J. Laskin, M. Kochenderfer et al., A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

, Ann Oncol, vol.26, issue.3, pp.556-61, 2015.

F. André, T. Bachelot, F. Commo, M. Campone, M. Arnedos et al., Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Lancet Oncol, vol.15, issue.3, pp.267-74, 2014.

L. Tourneau, C. Delord, J. P. Gonçalves, A. Gavoille, C. Dubot et al., Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, vol.16, issue.13, pp.1324-1358, 2015.

S. Cousin, T. Grellety, M. Toulmonde, C. Auzanneau, E. Khalifa et al., Clinical impact of extensive molecular profiling in advanced cancer patients, J Hematol Oncol, vol.10, issue.1, p.45, 2017.

C. Massard, S. Michiels, C. Ferté, L. Deley, M. C. Lacroix et al., High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov, vol.7, issue.6, pp.586-595, 2017.

, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, vol.517, issue.7536, pp.576-82, 2015.

M. G. Dalin, A. Desrichard, N. Katabi, V. Makarov, L. A. Walsh et al., Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer, Clin Cancer Res, vol.22, issue.18, pp.4623-4656, 2016.
DOI : 10.1158/1078-0432.ccr-16-0637

URL : http://clincancerres.aacrjournals.org/content/22/18/4623.full.pdf

R. Ferrarotto, Y. Mitani, L. Diao, I. Guijarro, J. Wang et al., Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors, J Clin Oncol, vol.35, issue.3, pp.352-360, 2017.

E. Massarelli, H. Lin, L. E. Ginsberg, H. T. Tran, J. J. Lee et al., Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.26, issue.7, pp.1476-80, 2015.

V. Grünwald, U. Keilholz, A. Boehm, O. Guntinas-lichius, B. Hennemann et al., TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin-and cetuximabrefractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO), Ann Oncol, 2015.